Skip to Content

Eventide Healthcare & Life Sciences A ETAHX

Medalist Rating as of | See Eventide Investment Hub
  • NAV / 1-Day Return 35.39  /  −1.17 %
  • Total Assets 1.6 Bil
  • Adj. Expense Ratio
    1.560%
  • Expense Ratio 1.560%
  • Distribution Fee Level High
  • Share Class Type Front Load
  • Category Health
  • Investment Style Small Growth
  • Min. Initial Investment 1,000
  • Status Open
  • TTM Yield
  • Turnover 79%

USD | NAV as of Mar 18, 2024 | 1-Day Return as of Mar 18, 2024, 10:14 PM GMT+0

Morningstar’s Analysis ETAHX

Will ETAHX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

This fund's track record comes with plenty of risks.

Senior Analyst David Kathman

David Kathman

Senior Analyst

Summary

Eventide Healthcare & Life Sciences is not a bad option within its narrow niche, though most investors should approach it with caution due to its inherent volatility. It maintains its pillar scores of Above Average for People and Average for Process.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings ETAHX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 32.6
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Zentalis Pharmaceuticals Inc Ordinary Shares

5.98 99.7 Mil
Healthcare

Celldex Therapeutics Inc

4.31 71.9 Mil
Healthcare

Karuna Therapeutics Inc

3.61 60.1 Mil
Healthcare

Us Bank Mmda - Usbgfs 9

3.11 51.8 Mil
Cash and Equivalents

Aura Biosciences Inc

3.08 51.4 Mil
Healthcare

Marinus Pharmaceuticals Inc

2.95 49.2 Mil
Healthcare

Cytokinetics Inc

2.78 46.4 Mil
Healthcare

Evolent Health Inc Class A

2.57 42.9 Mil
Healthcare

Exact Sciences Corp

2.51 41.8 Mil
Healthcare

Lexeo Therapeutics Inc

2.42 40.3 Mil
Healthcare